EGFR and non-small cell lung carcinoma: The findings indicate that the use of amivantamab + chemotherapy demonstrates superior efficacy compared to chemotherapy alone as a first-line treatment for patients with advanced NSCLC exhibiting EGFR exon 20 insertions.